ReviewAntibiotics (Basel, Switzerland)2022
Bacterial Co-Infection in Patients with COVID-19 Hospitalized (ICU and Not ICU): Review and Meta-Analysis.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Pooled it
- Pooled it
- Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Seven-year surveillance of antimicrobial resistance in respiratory pathogens at a Ugandan referral hospital: Emerging trends and stewardship priorities.African journal of thoracic and critical care medicine · 2025Article
- Coinfections and superinfections in critically ill COVID-19 patients in Ecuador: a cross-sectional study of bacterial and viral pathogens.Frontiers in public health · 2025Article
- Co-Infection of SARS-CoV-2 andDiagnostics (Basel, Switzerland) · 2024Review
- Article
- Antimicrobial Resistance in Qatar: Prevalence and Trends before and Amidst the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2024Article
- Serum Insulin-like Growth Factor-Binding Protein-2 as a Prognostic Factor for COVID-19 Severity.Biomedicines · 2024Article
- Emerging vaccine strategies against the incessant pneumococcal disease.NPJ vaccines · 2023Review
- Prevalence of early bacterial co-infection in hospitalized patients with COVID-19 pneumonia: a retrospective study.Journal of thoracic disease · 2023Article
- An Observational Study to Develop a Predictive Model for Bacterial Pneumonia Diagnosis in Severe COVID-19 Patients-C19-PNEUMOSCORE.Journal of clinical medicine · 2023Article
- Article
- The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections.Microorganisms · 2023Review
- A Retrospective Assessment of Sputum Samples and Antimicrobial Resistance in COVID-19 Patients.Pathogens (Basel, Switzerland) · 2023Article
- Antibiotic Usage in the COVID-19 Intensive Care Unit of an Infectious Diseases Hospital from Nord-Eastern Romania.Medicina (Kaunas, Lithuania) · 2023Article
- Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2023Review
- Review
- Novel evidence on sepsis-inducing pathogens: from laboratory to bedside.Frontiers in microbiology · 2023Review
- Problems Associated with Co-Infection by Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of patients hospitalized in ICUs with COVID-19 and co-infected by pathogenic bacteria is relevant in this study, considering the integrality of treatment. This systematic review assesses the prevalence of co-infection in patients admitted to ICUs with SARS-CoV-2 infection, using the PRISMA guidelines. We examined the results of the PubMed, Embase, and SciELO databases, searching for published English literature from December 2019 to December 2021. A total of 542 rec ords were identified, but only 38 were eligible and, and of these only 10 were included. The tabulated studies represented a sample group of 1394 co-infected patients. In total, 35%/138 of the patients were co-infected with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.